Marina De Brot1, Starr Koslow Mautner2, Shirin Muhsen2, Victor P Andrade1, Anita Mamtani2, Melissa Murray3, Dilip Giri3, Rita A Sakr2, Edi Brogi3, Tari A King4,5. 1. Department of Pathology, A.C.Camargo Cancer Center, Sao Paulo, SP, 01509-010, Brazil. 2. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. 4. Department of Surgery, Brigham and Women's Hospital, Boston, MA, 02115, USA. tking7@bwh.harvard.edu. 5. Surgical Oncology, Dana-Farber/Brigham and Women's Cancer Center, 450 Brookline Ave, Boston, MA, 02215, USA. tking7@bwh.harvard.edu.
Abstract
PURPOSE: The natural history of pleomorphic lobular carcinoma in situ (PLCIS) remains largely unknown. METHODS: A pathology database search (1995-2012) was performed to identify patients diagnosed with an LCIS variant. Patients with synchronous breast cancer and/or no evidence of pleomorphism were excluded. Original slides were re-evaluated by three pathologists to identify a consensus cohort of PLCIS. Borderline lesions with focal atypia were classified as LCIS with pleomorphic features (LCIS-PF). Clinical data were obtained from medical records. RESULTS: From 233 patients, we identified 32 with an LCIS variant diagnosis and no concurrent breast cancer. Following review, 16 cases were excluded due to lack of pleomorphism. The remaining 16 were classified as PLCIS (n = 11) and LCIS-PF (n = 5). 12/16 patients were treated with surgical excision ± chemoprevention. Patients with a prior breast cancer history and those having mastectomy were excluded from outcome analysis. Among the remaining 7 patients with PLCIS/LCIS-PF, 4/7 (57%) developed ipsilateral breast cancer at a median follow-up of 67 months. Median age at the time of breast cancer diagnosis was 56 years old and median time from PLCIS/LCIS-PF to cancer diagnosis was 59 months (range 45-66 months). The four cancers included 1 invasive lobular carcinoma (ILC), 1 microinvasive ILC, 1 invasive ductal carcinoma, and 1 ductal carcinoma in situ. CONCLUSIONS: We confirm that PLCIS in isolation is indeed a rare entity, further contributing to the difficulty in determining the actual risk conferred by this lesion. Long-term follow-up data on larger cohorts are needed to define standardized management and outcomes for patients with PLCIS.
PURPOSE: The natural history of pleomorphic lobular carcinoma in situ (PLCIS) remains largely unknown. METHODS: A pathology database search (1995-2012) was performed to identify patients diagnosed with an LCIS variant. Patients with synchronous breast cancer and/or no evidence of pleomorphism were excluded. Original slides were re-evaluated by three pathologists to identify a consensus cohort of PLCIS. Borderline lesions with focal atypia were classified as LCIS with pleomorphic features (LCIS-PF). Clinical data were obtained from medical records. RESULTS: From 233 patients, we identified 32 with an LCIS variant diagnosis and no concurrent breast cancer. Following review, 16 cases were excluded due to lack of pleomorphism. The remaining 16 were classified as PLCIS (n = 11) and LCIS-PF (n = 5). 12/16 patients were treated with surgical excision ± chemoprevention. Patients with a prior breast cancer history and those having mastectomy were excluded from outcome analysis. Among the remaining 7 patients with PLCIS/LCIS-PF, 4/7 (57%) developed ipsilateral breast cancer at a median follow-up of 67 months. Median age at the time of breast cancer diagnosis was 56 years old and median time from PLCIS/LCIS-PF to cancer diagnosis was 59 months (range 45-66 months). The four cancers included 1 invasive lobular carcinoma (ILC), 1 microinvasive ILC, 1 invasive ductal carcinoma, and 1 ductal carcinoma in situ. CONCLUSIONS: We confirm that PLCIS in isolation is indeed a rare entity, further contributing to the difficulty in determining the actual risk conferred by this lesion. Long-term follow-up data on larger cohorts are needed to define standardized management and outcomes for patients with PLCIS.
Entities:
Keywords:
Breast cancer; High-risk lesion; Lobular carcinoma in situ; Pleomorphic lobular carcinoma in situ; Recurrence
Authors: Meghan R Flanagan; Mara H Rendi; Kristine E Calhoun; Benjamin O Anderson; Sara H Javid Journal: Ann Surg Oncol Date: 2015-04-17 Impact factor: 5.344
Authors: Tari A King; Melissa Pilewskie; Shirin Muhsen; Sujata Patil; Starr K Mautner; Anna Park; Sabine Oskar; Elena Guerini-Rocco; Camilla Boafo; Jessica C Gooch; Marina De Brot; Jorge S Reis-Filho; Mary Morrogh; Victor P Andrade; Rita A Sakr; Monica Morrow Journal: J Clin Oncol Date: 2015-09-14 Impact factor: 44.544
Authors: David J Dabbs; Stuart J Schnitt; Felipe C Geyer; Britta Weigelt; Frederick L Baehner; Thomas Decker; Vincenzo Eusebi; Stephen B Fox; Shu Ichihara; Sunil R Lakhani; Jose Palacios; Emad Rakha; Andrea L Richardson; Fernando C Schmitt; Puay-Hoon Tan; Gary M Tse; Anne Vincent-Salomon; Ian O Ellis; Sunil Badve; Jorge S Reis-Filho Journal: Am J Surg Pathol Date: 2013-07 Impact factor: 6.394
Authors: Lauren J Taylor; Jennifer Steiman; Jessica R Schumacher; Lee G Wilke; Caprice C Greenberg; Heather B Neuman Journal: Ann Surg Oncol Date: 2018-05-31 Impact factor: 5.344
Authors: Beth T Harrison; Faina Nakhlis; Deborah A Dillon; T Rinda Soong; Elizabeth P Garcia; Stuart J Schnitt; Tari A King Journal: Mod Pathol Date: 2020-01-13 Impact factor: 7.842
Authors: M Gabriela Kuba; Melissa P Murray; Kristen Coffey; Catarina Calle; Monica Morrow; Edi Brogi Journal: Mod Pathol Date: 2021-04-06 Impact factor: 7.842